Mark Charest, PhDPortfolio Manager

    Mark Charest, PhD, is portfolio manager of the AlphaCentric LifeSci Healthcare Fund. Mark has a distinguished scientific background and more than a decade of institutional healthcare investing experience.  He is an inventor on 8 drug patents* including one related to an approved drug used to treat complicated intra-abdominal infections.

    A well respected and successful investor and scientist, Mark led a Medicinal Chemistry Lab at the Novartis Institutes for BioMedical Research after earning his PhD in chemistry and chemical biology from Harvard University. He is a National Science Foundation Graduate Research Fellow and earned his B.A. in Chemistry with the highest honors from Rutgers University.

    His distinguished career includes the completion of noble prize-winning chemist RB Woodward’s work on chemical synthesis of tetracycline. This work led to an approved drug and intellectual property out-licensed to found Tetraphase Pharmaceuticals.

    After successfully running a lab at Novartis as a Medicinal Chemistry Lab Manager in the Oncology Group, and successfully putting a drug into clinical trials, Mark transitioned to Wall Street. He has held positions as a Portfolio Manager at New Leaf Venture Partners, an SVP at Tekla Capital Management, and an Associate at Great Point Partners; several specialized $1B+ AUM healthcare technology funds.

    Mark was a Kauffman Fellow at Panorama Capital focused on private and public healthcare technology investments. He served on the board of directors of Itero Biopharmaceuticals and was a board observer at Presidio Pharmaceuticals and PowerVision. He was the recipient of the 2012 Jeff Timmons Memorial Award in recognition of his contributions to the Kauffman Fellows organization and service to the Kauffman Fellows Program.

    Mark lives in San Juan, Puerto Rico. Outside of work he maintains an athletic and active schedule often competing in beach volleyball tournaments. He enjoys playing golf, is a connoisseur of wine and beer, and is an avid reader citing The Intelligent Investor and The Art of War as two of his favorite novels.

    The AlphaCentric LifeSci Capital Healthcare Fund leverages the hands-on scientific achievements of Mark to invest in biotech and healthcare equities and the experience of 20+ PhDs and MDs with the objective of seeking long-term appreciation. LifeSci Partners is the leading provider of strategic scientific consulting services in the areas of investor relations, public relations, corporate communications, executive search, and capital markets advisory. Combining deep domain expertise in the life sciences with decades of experience in capital markets and corporate communications, LifeSci Partners delivers unparalleled services to life sciences companies globally.

    With global presences in New York, Chicago, Boston, London, Geneva, Paris, Asia, and Tel-Avis, LifeSci Partners leverages its relationships and local knowledge in multiple territories around the world to provide high value services for clients.

    Mark’s investment mindset is fundamental where he converges science, clinical, and medical technical aspects with valuation, cash flow, and balance sheet considerations.  His comprehensive primary research and key opinion leader insights are curated across the global LifeSci platform. His differentiators remain his investment discipline and his willingness to take contrarian views.

     

    *Patents

    “Synthesis of Tetracyclines and Analogues Thereof.” Andrew G. Myers, Mark G. Charest, Christian D. Lerner, Jason D. Bruaker and Dionicio R. Siegel, U.S. Patent 8,598,148; December 3, 2013 and U.S. Patent 9,365,493; June 14, 2016.”

    “Inhibitors of IAP.” Mark G. Palermo, Sushil K. Sharma, Christopher Straub, Run Ming Wang, Leigh S. Zawel , Yanlin Zhang, Zhuoliang Chen, Yaping Wang, Fan Yang, Wojciech Wrona, Gang Liu, Mark G. Charest and Feng He, U.S. Patent 8,338,440; December 25, 2012 and U.S. Patent 8,207,183; June 26, 2012.“

    “Pyrrolydine Derivatives as IAP Inhibitors.” Mark G. Charest, Christine Hiu Ting Chen, Ming Chen, Miao Dai, Feng He, Huangshu Lei, Christopher Straub, Run Ming Wang, and Leigh S. Zawel , U.S. Patent 8,044,209; October 25, 2011”

    “Synthesis of Tetracyclines and Analogues Thereof.” Andrew G. Myers, Mark G. Charest, Christian D. Lerner, Jason D. Bruaker and Dionicio R. Siegel, U.S. Patent 7,807,842; October 5, 2010.”

    “Organic Compounds.” Mark G. Palermo, Sushil K. Sharma, Christopher Straub, Run Ming Wang, Leigh S. Zawel , Yanlin Zhang, Zhuoliang Chen, Yaping Wang, Fan Yang, Wojciech Wrona , Gang Liu, Mark G. Charest and Feng He, U.S. Patent 7,419,975; September 2, 2008.”

    “Preparation of α Hydroxy γ carbocyclic or heterocyclic substituted)amino]carbonyl] alkanamides as HIV Protease Inhibitors James R Tata, Zhijian Lu, Subharekha Raghavan Tracy T Huening Thomas A Rano and Mark G Charest, U S Patent 6 589 962 July 8 2003”